DIETARY COMPOSITION, OBESITY, AND CARDIOVASCULAR RISK
DIETARY COMPOSITION, OBESITY, AND CARDIOVASCULAR RISK
批准号:
6183821
负责人:
ERNST JOHN SCHAEFER
金额:
$39.48万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-07-01 至 2004-05-31
关键词:
basal metabolism bioenergetics blood lipoprotein body composition body physical activity body weight caloric dietary content cholesterol clinical research coronary disorder diet therapy dietary carbohydrates dietary control dietary lipid dietary restriction disease /disorder proneness /risk glycation hemoglobin As human middle age (35-64) human subject human therapy evaluation nutrient intake activity nutrition related tag obesity postmenopause
中文摘要
冠心病(CHD)是当今社会死亡和致残的主要原因。肥胖会对血糖、脂蛋白和血压产生不利影响,从而增加患冠心病的风险。限制饮食饱和脂肪和胆固醇(C)有利于降低低密度脂蛋白(LDL)和降低冠心病风险已成为共识,但对饮食的其他方面存在争议。我们建议考察三种符合国家胆固醇教育计划第二步饮食标准的饮食对体重和组成的影响,以及对空腹和非空腹状态(餐后4小时)的CHD危险因素(低密度脂蛋白、高密度脂蛋白C、残余脂蛋白C、胰岛素、糖化血红蛋白、血糖和血压)的影响。将进行四个阶段的研究,在前三个阶段提供所有食物和饮料,而在第四阶段建议提供饮食但不提供。在第一阶段,所有受试者最初将接受为期5周的平均等量美国饮食(15%蛋白质,35%脂肪;15%饱和脂肪;15%单不饱和脂肪;6%多不饱和脂肪,含150毫克胆固醇/1000卡路里和10克/1000卡路里)。光纤)。在第二阶段,受试者将被平等地随机分成三种饮食之一,均含有15%的蛋白质、5%的饱和脂肪和60毫克的胆固醇/1000卡路里:1)高复合碳水化合物(CHO):15%的脂肪、5%的单一碳水化合物、5%的多聚糖和70%的CHO(主要是复合的,血糖指数相对较高),16g/1000卡路里的纤维,以及1.10卡路里/克的低饮食热量密度;2)高单体:与饮食1相同,只是脂肪含量为30%(15%Mono)和55%CHO,具有高血糖指数和高热量密度的CHO,1.25卡/克;以及3)综合:与饮食2相同,只是血糖指数较低,饮食热量密度为1.10克/1000卡)。这些饮食将被随意给予,受试者可以使用200卡路里的砂锅菜来调整他们的卡路里水平,从维持体重所需卡路里的66%到133%,持续12周。在第三阶段,受试者将在受控情况下继续同样的饮食8周,再持续5周,然后在不受控制的情况下继续一年(阶段4),在那里他们将接受饮食指导和菜单,但不接受食物。体重和血压将每周评估三次,血浆脂蛋白(低密度脂蛋白、高密度脂蛋白、残留物和Lp[a])、血糖、糖化血红蛋白和胰岛素水平将在禁食状态下评估三次,在每个受控饮食期结束时和在长期随访期的3、6、9和12个月时评估一次。此外,在所有阶段将定期测量体重、身体能量消耗、体力活动、身体成分、人体测量学和代谢率。我们的假设是,富含复合碳水化合物、低热量密度的限脂饮食和低热量密度、低血糖指数的复合饮食对冠心病危险因素、体重、体成分和能量消耗的影响比单脂、血糖指数和热量密度高的2级饮食更有利。
英文摘要
Coronary heart disease (CHD) is a major cause of death and disability in our society. Obesity increases CHD risk by adversely affecting glucose, lipoproteins, and blood pressure. There is consensus that dietary saturated fat and cholesterol (C) restriction is beneficial for low density lipoprotein (LDL) lowering and CHD risk reduction, but there controversy about other aspects of the diet. We propose to examine the effects of three diets meeting National Cholesterol Education program Step 2 diet criteria on body weight and composition and on CHD risk factors (LDL C, HDL C, remnant lipoprotein C, Lp(a) C, insulin, glycosylated hemoglobin, glucose, and blood pressure) in the fasting and nonfasting state (4 hours after a meal) in 80 men and women (men greater than or equal to 50 and less than 65 years of age, women postmenopausal and less than 65) with LDL C values greater than or equal to 130 mg/dI and a body mass index greater than or equal to 28 and less than 38 kg/m2. A four phase study will be conducted in which all food and drink is provided during the first 3 phases, while diet is recommended but not provided in the fourth phase. In phase 1, all subjects will initially be placed on an average isoweight U.S. diet for 5 weeks (15 percent protein, 35 percent fat; 15 percent saturated fat; 15 percent monounsaturated (mono) fat; 6 percent polyunsaturated (poly) fat, with 150 mg of cholesterol/1000 calories and 10 g/1000 cal. of fiber). For phase 2, subjects will then be equally randomized to one of 3 diets, all containing 15 percent protein, 5 percent saturated fat and 60 mg of cholesterol/1000 calories: 1) high complex carbohydrate (CHO): 15 percent fat, 5 percent mono, 5 percent poly, and 70 percent CHO (mainly complex with relatively high glycemic index), 16 g/1000 cal of fiber, and low dietary caloric density of 1.10 cal/gm; 2) high mono: identical to diet 1 except that the fat content will be 30 percent (15 percent mono) and 55 percent CHO with CHO of high glycemic index and high caloric density, 1.25 cal/gm; and 3) composite: identical to diet 2 except that there will be lower glycemic index and low dietary caloric density of 1.10 g/1000 cal). These diets will be given ad libitum, and subjects can adjust their calorie level using 200 calorie casseroles from 66 percent to 133 percent of calories needed to maintain weight, for a 12 week period. Subjects will then be continued on these same diets isoweight for an additional 5 weeks under controlled circumstances in phase 3, and then for one year (phase 4) under uncontrolled circumstances where they will receive dietary instruction and menus, but not food. Body weight and blood pressure will be assessed three times per week, and plasma lipoproteins (LDL, HDL, remnants, and Lp[a]), glucose, glycosylated hemoglobin, and insulin levels will be assessed three times in the fasting state and once in the fed state at the end of each controlled dietary period and at 3, 6, 9, and 12 months in the long-term follow-up period. In addition, body weight, body energy expenditure, physical activity, body composition, anthropometics, and metabolic rate will be measured at regular intervals during all phases. Our hypothesis is that the fat-restricted diet rich in complex carbohydrate and low in caloric density and the composite diet low in caloric density and glycemic index will have a more favorable effect on CHD risk factors, body weight, body composition and energy expenditure than the Step 2 diet higher in mono fat, glycemic index, and caloric density.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Core--Laboratory and Data Management
-
批准号:7140959
-
项目类别:
-
资助金额:$21.03万
-
财政年份:2006
-
负责人:ERNST JOHN SCHAEFER
-
依托单位:
EFFECTS OF EXTENDED-RELEASE NIACIN ON A COMBINATION OF LOVASTATIN
-
批准号:7200872
-
项目类别:
-
资助金额:$0.77万
-
财政年份:2005
-
负责人:ERNST JOHN SCHAEFER
-
依托单位:
Effects of Extended-Release Niacin on a Combination
-
批准号:7040665
-
项目类别:
-
资助金额:$0.05万
-
财政年份:2004
-
负责人:ERNST JOHN SCHAEFER
-
依托单位:
Effects of Atorvastatin on the Kinetics of APO B-100
-
批准号:7040659
-
项目类别:
-
资助金额:$0.47万
-
财政年份:2004
-
负责人:ERNST JOHN SCHAEFER
-
依托单位:
Pharmacogenetics of the Statin Response
-
批准号:7119521
-
项目类别:
-
资助金额:$81.7万
-
财政年份:2003
-
负责人:ERNST JOHN SCHAEFER
-
依托单位:
Pharmacogenetics of the Statin Response
-
批准号:6805273
-
项目类别:
-
资助金额:$79.13万
-
财政年份:2003
-
负责人:ERNST JOHN SCHAEFER
-
依托单位:
Pharmacogenetics of the Statin Response
-
批准号:6698877
-
项目类别:
-
资助金额:$70.3万
-
财政年份:2003
-
负责人:ERNST JOHN SCHAEFER
-
依托单位:
Pharmacogenetics of the Statin Response
-
批准号:6933896
-
项目类别:
-
资助金额:$83.68万
-
财政年份:2003
-
负责人:ERNST JOHN SCHAEFER
-
依托单位:
MOLECULAR BASIS OF HIGH DENSITY LIPOPROTEIN DEFICIENCY
-
批准号:2854266
-
项目类别:
-
资助金额:$30.04万
-
财政年份:1999
-
负责人:ERNST JOHN SCHAEFER
-
依托单位:
Molecular Basis of High Density Lipoprotein Deficiency
-
批准号:7054062
-
项目类别:
-
资助金额:$31.46万
-
财政年份:1999
-
负责人:ERNST JOHN SCHAEFER
-
依托单位:
Molecular Basis of High Density Lipoprotein Deficiency
-
批准号:6926809
-
项目类别:
-
资助金额:$31.7万
-
财政年份:1999
-
负责人:ERNST JOHN SCHAEFER
-
依托单位:
Molecular Basis of High Density Lipoprotein Deficiency
-
批准号:7416663
-
项目类别:
-
资助金额:$33.82万
-
财政年份:1999
-
负责人:ERNST JOHN SCHAEFER
-
依托单位:
DIETARY COMPOSITION, OBESITY, AND CARDIOVASCULAR RISK
-
批准号:6537285
-
项目类别:
-
资助金额:$41.89万
-
财政年份:1999
-
负责人:ERNST JOHN SCHAEFER
-
依托单位:
DIETARY COMPOSITION, OBESITY, AND CARDIOVASCULAR RISK
-
批准号:2909036
-
项目类别:
-
资助金额:$39.12万
-
财政年份:1999
-
负责人:ERNST JOHN SCHAEFER
-
依托单位:
MOLECULAR BASIS OF HIGH DENSITY LIPOPROTEIN DEFICIENCY
-
批准号:6165080
-
项目类别:
-
资助金额:$27.92万
-
财政年份:1999
-
负责人:ERNST JOHN SCHAEFER
-
依托单位:
Molecular Basis of High Density Lipoprotein Deficiency
-
批准号:7623881
-
项目类别:
-
资助金额:$33.36万
-
财政年份:1999
-
负责人:ERNST JOHN SCHAEFER
-
依托单位:
DIETARY COMPOSITION, OBESITY, AND CARDIOVASCULAR RISK
-
批准号:6638463
-
项目类别:
-
资助金额:$17.63万
-
财政年份:1999
-
负责人:ERNST JOHN SCHAEFER
-
依托单位:
MOLECULAR BASIS OF HIGH DENSITY LIPOPROTEIN DEFICIENCY
-
批准号:6363558
-
项目类别:
-
资助金额:$28.53万
-
财政年份:1999
-
负责人:ERNST JOHN SCHAEFER
-
依托单位:
DIETARY COMPOSITION, OBESITY, AND CARDIOVASCULAR RISK
-
批准号:6389608
-
项目类别:
-
资助金额:$40.67万
-
财政年份:1999
-
负责人:ERNST JOHN SCHAEFER
-
依托单位:
MECHANISM OF INCREASED PLASMA APO A1 LEVELS BY ESTROGENS
-
批准号:6304531
-
项目类别:
-
资助金额:$4.27万
-
财政年份:1999
-
负责人:ERNST JOHN SCHAEFER
-
依托单位:
海外基金